Shares of Inotek Pharmaceuticals (NASDAQ: ITEK), a small-cap biopharma with a focus on diseases of the eye, dropped more than 20% during the month of September.
What caused such a huge sell-off? See the presentation below for details.
Is the huge sell-off justified? Or is now a good time to pick up shares?
Shares of Inotek Pharmaceuticals (NASDAQ: ITEK), a small-cap biopharma with a focus on diseases of the eye, dropped more than 20% during the month of September.
What caused such a huge sell-off? See the presentation below for details.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.